{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Autologous Osteoblastic Cell Therapy versus Bone Marrow Aspirate Concentrate in Pre-collapse Osteonecrosis of the Femoral Head"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "randomised, single-blind trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "67 patients with Stage I or II ONFH, excluding those with traumatic ONFH, hemoglobinopathies, or positive serology for hepatitis B, C, or HIV"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomly assigned to core decompression with either BMAC (n = 26) or osteoblastic cell therapy (n = 30)"
      },
      "Objective": {
        "score": 1,
        "evidence": "assessed whether autologous osteoblastic cell therapy could reduce progression to subchondral fracture and improve pain compared to bone marrow aspirate concentrate"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the absence of progression to subchondral fracture (ARCO stage III or higher) and a clinically important pain improvement over 36 months"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was achieved using a computer-generated sequence, with allocation concealment"
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "randomly assigned to core decompression with either BMAC (n = 26) or osteoblastic cell therapy (n = 30)"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "The analysis was conducted as-treated for efficacy and intention-to-treat for adverse events"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "no significant differences were found in progression to fracture (46% BMAC vs. 22% osteoblastic cells; hazard ratio, 0.47 [95% CI 0.17 to 1.31]; p = 0.15)"
      },
      "Harms": {
        "score": 1,
        "evidence": "No differences were observed in THA rates (15% osteoblastic cells vs. 35% BMAC; p = 0.09) or adverse events"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: Not provided"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not reported"
      }
    },
    "total_score": 18,
    "max_score": 25
  },
  "model": "gpt-4o"
}